GLMD logo

Galmed Pharmaceuticals Stock Price

Symbol: NasdaqCM:GLMDMarket Cap: US$8.9mCategory: Pharmaceuticals & Biotech

GLMD Share Price Performance

US$1.60
-1.77 (-52.48%)
US$1.60
-1.77 (-52.48%)
Price US$1.60

GLMD Community Narratives

There are no narratives available yet.

GLMD Community Fair Values

    Recent GLMD News & Updates

    No updates

    Galmed Pharmaceuticals Ltd. Key Details

    US$0

    Revenue

    US$0

    Cost of Revenue

    US$0

    Gross Profit

    US$7.3m

    Other Expenses

    -US$7.3m

    Earnings

    Last Reported Earnings
    Mar 31, 2025
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    -1.35
    Gross Margin
    0%
    Net Profit Margin
    0%
    Debt/Equity Ratio
    0%

    Galmed Pharmaceuticals Ltd. Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About GLMD

    Founded
    2000
    Employees
    5
    CEO
    Allen Baharaff
    WebsiteView website
    galmedpharma.com

    Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of Aramchol for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule for the treatment of non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study for HIV-associated lipodystrophy and non-alcoholic fatty liver disease. In addition, it develops products for cardiometabolic indications. The company has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with Virginia Commonwealth University to investigate the effect of adding Aramchol to prevent drug resistance to standard-of-care oncology agents in the treatment of hepatoma, cholangiocarcinoma, and colorectal cancer. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

    Israeli Market Performance

    • 7 Days: -4.0%
    • 3 Months: 13.4%
    • 1 Year: 61.8%
    • Year to Date: 24.3%
    Over the last 7 days, the market has dropped 4.0%, driven by a loss of 4.6% in the Financials sector. In the last year, the market is actually up 62%. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading